Expert opinion on hot topics in the field of IBD
Year: 2025
Type: article
Abstract: • SC formulations of infliximab and vedolizumab demonstrated effectiveness, patients’ and physicians’ preferences, and cost savings. SC formulations of IV biologics could thus be considered whenever a patient prefers this route of administration. • When abdominal surgery is required in IBD, efforts should be made for reducing steroid exposure, assessing malnutrition, initiating nutritional support. The use of biologics is safe in the preoperative period. • Anti-IL23 therapies have demonstrated strong efficacy and satisfactory safety profile in moderate-to-severe CD and UC and will shortly become part of the daily IBD therapeutic arsenal.
Institutions: Inserm, Centre Hospitalier Universitaire de Besançon, Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, Université de Franche-Comté, Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Grenoble, Institut pour l'avancée des biosciences, Université Grenoble Alpes, Centre Hospitalier Universitaire Amiens-Picardie, Périnatalité & Risques Toxiques, Université de Picardie Jules Verne, Université Paris-Saclay, Assistance Publique – Hôpitaux de Paris, Centre de recherche en Epidémiologie et Santé des Populations, Bicêtre Hospital, Centre Hospitalier Régional et Universitaire de Nancy, Université de Lorraine
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,260
OpenAlex ID: W4416028887